Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
East Syracuse, NY
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
East Syracuse, NY
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Johnson City, NY
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Johnson City, NY
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Gastonia, NC
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Gastonia, NC
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Hickory, NC
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Pinehurst, NC
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Pinehurst, NC
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Massillon, OH
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Massillon, OH
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Zanesville, OH
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Zanesville, OH
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Bend, OR
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Bethlehem, PA
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Langhorne, PA
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Langhorne, PA
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Florence, SC
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Florence, SC
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Watertown, SD
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Watertown, SD
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Bristol, TN
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Bristol, TN
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Chattanooga, TN
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Corpus Christi, TX
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Corpus Christi, TX
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Plano, TX
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Ogden, UT
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Chesapeake, VA
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Spokane, WA
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Huntington, WV
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Huntington, WV
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Janesville, WI
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Janesville, WI
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Madison, WI
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Racine, WI
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Racine, WI
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Wauwatosa, WI
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Weston, WI
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Weston, WI
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Mount Sterling, KY
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Mount Sterling, KY
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Saint Cloud, MN
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Saint Louis, MO
NOLAN: Naproxen or Loratadine and Neulasta
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Diagnostic Feasibility Trial of a [14C]Oxaliplatin Microdosing Assay for Prediction of Chemoresistance to Oxaliplatin Chemotherapy
Status: Enrolling
Updated:  1/5/2018
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Diagnostic Feasibility Trial of a [14C]Oxaliplatin Microdosing Assay for Prediction of Chemoresistance to Oxaliplatin Chemotherapy
Status: Enrolling
Updated: 1/5/2018
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Breast Cancer Tumor Heterogeneity
Does Breast Tumor Heterogeneity Necessitate Additional HER2 Testing on the Surgical Specimens?
Status: Enrolling
Updated:  1/8/2018
Anne Arundel Medical Center
mi
from
Annapolis, MD
Breast Cancer Tumor Heterogeneity
Does Breast Tumor Heterogeneity Necessitate Additional HER2 Testing on the Surgical Specimens?
Status: Enrolling
Updated: 1/8/2018
Anne Arundel Medical Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
Status: Enrolling
Updated:  1/8/2018
Eleanor N. Dana Cancer Center, University of Toledo
mi
from
Toledo, OH
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
Status: Enrolling
Updated: 1/8/2018
Eleanor N. Dana Cancer Center, University of Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel
Cold Therapy to Prevent Paclitaxel-Induced Peripheral Neuropathy and Cutaneous Toxicity
Status: Enrolling
Updated:  1/9/2018
Northwestern University
mi
from
Chicago, IL
Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel
Cold Therapy to Prevent Paclitaxel-Induced Peripheral Neuropathy and Cutaneous Toxicity
Status: Enrolling
Updated: 1/9/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
COGNUTRIN in Breast Cancer Survivors
Pilot Clinical Trial of COGNUTRIN in Breast Cancer Survivors
Status: Enrolling
Updated:  1/9/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
COGNUTRIN in Breast Cancer Survivors
Pilot Clinical Trial of COGNUTRIN in Breast Cancer Survivors
Status: Enrolling
Updated: 1/9/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG
A Phase I-II Study of Acupuncture for the Treatment of Chronic, Taxane-Induced Peripheral Neuropathy in Breast Cancer Survivors
Status: Enrolling
Updated:  1/10/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG
A Phase I-II Study of Acupuncture for the Treatment of Chronic, Taxane-Induced Peripheral Neuropathy in Breast Cancer Survivors
Status: Enrolling
Updated: 1/10/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/10/2018
Yale University Smilow Cancer Hospital
mi
from
New Haven, CT
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/10/2018
Yale University Smilow Cancer Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  1/10/2018
GSK Clinical Trials Call Center
mi
from
San Francisco, CA
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 1/10/2018
GSK Clinical Trials Call Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer
Pilot Study of Hepatic Arterial Infusion (HAI) With Oxaliplatin, Folinic Acid and 5 Fluorouracil (FOLFOX) in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Breast Cancer
Status: Enrolling
Updated:  1/11/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer
Pilot Study of Hepatic Arterial Infusion (HAI) With Oxaliplatin, Folinic Acid and 5 Fluorouracil (FOLFOX) in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Breast Cancer
Status: Enrolling
Updated: 1/11/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
A Randomized Trial to Evaluate the Benefit of High Dose Vitamin D3 on Aromatase Inhibitor Letrozole-Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).
Status: Enrolling
Updated:  1/11/2018
University of Kansas Medical Center
mi
from
Westwood, KA
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
A Randomized Trial to Evaluate the Benefit of High Dose Vitamin D3 on Aromatase Inhibitor Letrozole-Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).
Status: Enrolling
Updated: 1/11/2018
University of Kansas Medical Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
A Randomized Trial to Evaluate the Benefit of High Dose Vitamin D3 on Aromatase Inhibitor Letrozole-Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).
Status: Enrolling
Updated:  1/11/2018
Cancer Centers of Kansas, P.A.
mi
from
Wichita, KA
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
A Randomized Trial to Evaluate the Benefit of High Dose Vitamin D3 on Aromatase Inhibitor Letrozole-Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).
Status: Enrolling
Updated: 1/11/2018
Cancer Centers of Kansas, P.A.
mi
from
Wichita, KA
Click here to add this to my saved trials
High Resolution 3D Diffusion-weighted Breast MRI
High Resolution 3D Diffusion-weighted Breast MRI
Status: Enrolling
Updated:  1/12/2018
Stanford University School of Medicine
mi
from
Stanford, CA
High Resolution 3D Diffusion-weighted Breast MRI
High Resolution 3D Diffusion-weighted Breast MRI
Status: Enrolling
Updated: 1/12/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
Acrc/Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
Acrc/Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
Rita Nanda, MD
mi
from
Chicago, IL
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
Rita Nanda, MD
mi
from
Chicago, IL
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
St. Luke'S Cancer Institute
mi
from
Kansas City, MO
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
St. Luke'S Cancer Institute
mi
from
Kansas City, MO
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials